Provided by Tiger Trade Technology Pte. Ltd.

Sarepta Therapeutics

20.52
-1.5000-6.81%
Post-market: 20.50-0.0200-0.10%16:08 EDT
Volume:2.20M
Turnover:45.53M
Market Cap:2.17B
PE:-15.59
High:22.02
Open:22.02
Low:20.28
Close:22.02
52wk High:25.32
52wk Low:14.68
Shares:105.57M
Float Shares:99.05M
Volume Ratio:0.53
T/O Rate:2.22%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3161
EPS(LYR):-7.1300
ROE:-9.48%
ROA:-1.13%
PB:1.42
PE(LYR):-2.88

Loading ...

Sarepta Therapeutics Appoints Michael Severino, M.d., Chief Executive Officer

THOMSON REUTERS
·
Jul 27

Press Release: Sarepta Therapeutics to Announce Second Quarter 2026 Financial Results

Dow Jones
·
Jul 22

Analysts Offer Insights on Healthcare Companies: Compugen (CGEN), Telix Pharmaceuticals (OtherTLPPF) and Sarepta Therapeutics (SRPT)

TIPRANKS
·
Jul 22

Has Sarepta Therapeutics (SRPT) Fallen Below Fair Value After FDA Progress?

Simply Wall St.
·
Jul 19

Is Sarepta Therapeutics (SRPT) Undervalued Following FDA Progress On AMONDYS 45 And VYONDYS 53?

Simply Wall St.
·
Jul 15

Analysts Offer Insights on Healthcare Companies: Forte Biosciences (FBRX), Sarepta Therapeutics (SRPT) and Opus Genetics (IRD)

TIPRANKS
·
Jul 10

Sarepta Therapeutics Raised to Outperform from Peer Perform by Wolfe Research

Dow Jones
·
Jul 09

Sarepta price target lowered to $20 from $23 at Piper Sandler

TIPRANKS
·
Jul 09

Sarepta upgraded to Outperform from Peer Perform at Wolfe Research

TIPRANKS
·
Jul 09

Why Sarepta Therapeutics (SRPT) Is Up 12.7% After FDA Accepts sNDAs Backed By ESSENCE Data

Simply Wall St.
·
Jul 08

H.C. Wainwright says Sarepta news does not signal full approvals

TIPRANKS
·
Jul 01

Sarepta Grants 151,305 Rsus to 30 New Hires Under 2024 Incentive Plan

Reuters
·
Jul 01

Sarepta Therapeutics Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

THOMSON REUTERS
·
Jul 01

Sarepta Shares up on FDA Acceptance of Supplemental New Drug Applications

Dow Jones
·
Jul 01

Sarepta Therapeutics Gets FDA Review for Duchenne Muscular Dystrophy Applications

MT Newswires Live
·
Jun 30

Sarepta Says FDA Accepts Amondys 45, Vyondys 53 Sndas for Review, Sets Feb. 28, 2027 PDUFA Date

Reuters
·
Jun 30

Sarepta Therapeutics - FDA Sets Pdufa Target Action Date of February 28, 2027

THOMSON REUTERS
·
Jun 30

Sarepta Announces FDA Acceptance of Sndas for Amondys 45® and Vyondys 53®

THOMSON REUTERS
·
Jun 30

Analysts Offer Insights on Healthcare Companies: Sarepta Therapeutics (SRPT), Eli Lilly & Co (LLY) and C4 Therapeutics (CCCC)

TIPRANKS
·
Jun 22

Barclays Sticks to Its Hold Rating for Sarepta Therapeutics (SRPT)

TIPRANKS
·
Jun 22